A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Savara Inc stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 448,360 shares of SVRA stock, worth $1.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
448,360
Previous 392,723 14.17%
Holding current value
$1.9 Million
Previous $1.96 Million 7.62%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$3.66 - $5.34 $203,631 - $297,101
55,637 Added 14.17%
448,360 $1.81 Million
Q1 2024

May 09, 2024

BUY
$4.19 - $5.59 $520,716 - $694,702
124,276 Added 46.29%
392,723 $1.96 Million
Q4 2023

Feb 09, 2024

BUY
$3.18 - $4.9 $134,253 - $206,868
42,218 Added 18.66%
268,447 $1.26 Million
Q3 2023

Nov 13, 2023

SELL
$2.97 - $3.88 $39,881 - $52,100
-13,428 Reduced 5.6%
226,229 $855,000
Q2 2023

Aug 10, 2023

BUY
$1.69 - $3.24 $54,098 - $103,715
32,011 Added 15.42%
239,657 $764,000
Q1 2023

May 09, 2023

BUY
$1.6 - $2.82 $52,116 - $91,855
32,573 Added 18.61%
207,646 $404,000
Q4 2022

Feb 10, 2023

BUY
$1.11 - $1.64 $3,505 - $5,179
3,158 Added 1.84%
175,073 $271,000
Q3 2022

Nov 10, 2022

BUY
$1.36 - $1.88 $37,376 - $51,668
27,483 Added 19.03%
171,915 $266,000
Q2 2022

Aug 05, 2022

BUY
$1.1 - $1.58 $10,299 - $14,793
9,363 Added 6.93%
144,432 $220,000
Q1 2022

May 12, 2022

SELL
$1.05 - $1.36 $17,146 - $22,208
-16,330 Reduced 10.79%
135,069 $177,000
Q4 2021

Feb 10, 2022

SELL
$1.04 - $1.34 $12,631 - $16,275
-12,146 Reduced 7.43%
151,399 $188,000
Q3 2021

Nov 12, 2021

BUY
$1.18 - $1.64 $23,556 - $32,739
19,963 Added 13.9%
163,545 $226,000
Q2 2021

Aug 12, 2021

BUY
$1.51 - $2.29 $163,010 - $247,214
107,954 Added 303.0%
143,582 $244,000
Q1 2021

May 13, 2021

BUY
$1.17 - $2.33 $41,684 - $83,013
35,628 New
35,628 $74,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $484M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.